ENTRY       D12282                      Drug
NAME        Motixafortide acetate (USAN);
            Aphexda (TN)
PRODUCT     APHEXDA (BioLineRx USA)
FORMULA     C97H144FN33O19S2. (C2H4O2)x
REMARK      Chemical structure group: DG03214
            Product (DG03214): D12282<US>
EFFICACY    Antineoplastic
  DISEASE   Multiple myeloma [DS:H00010]
COMMENT     Indicated in combination with filgrastim [DR:D03235] to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
TARGET      CXCR4 (CD184) [HSA:7852] [KO:K04189]
  PATHWAY   hsa04060(7852)  Cytokine-cytokine receptor interaction
            hsa04062(7852)  Chemokine signaling pathway
            hsa05200(7852)  Pathways in cancer
BRITE       Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Chemokine receptors
                CXCR4 (CD184)
                 D12282  Motixafortide acetate (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12282
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12282
DBLINKS     CAS: 2639893-42-6
///
